← Back to Home

Sudarshan Pharma Ends MedTherapy Stake Acquisition, Halting Cross-Border Cell Therapy Plans

Just one month elapsed between board approval and the announcement terminating an investment proposal linking Boston technology with Indian manufacturing. The company and two promoters had planned to acquire a combined 12.5% stake. The plan has now ended, with no clear explanation yet for the cancellation.

By SURL BioNews

An investment intended to bring an Indian pharmaceutical company into the cancer cell therapy market has ended before completion. Sudarshan Pharma Industries disclosed to the stock exchange on October 7, 2026, that it had terminated its acquisition of a 9.5% stake in US-based MedTherapy Biotechnology. Plans for two company promoters to acquire a 1.5% stake each were also terminated.

This marks a substantive turn in the cross-border plans announced in early September. Sudarshan Pharma’s board approved the investment proposal on September 5. The company had planned to pay the consideration in US dollars in cash, targeting completion by March 31, 2027. Together with the individual investments by Hemal Mehta and Sachin Mehta, the three parties had planned to hold a combined 12.5% stake in MedTherapy, rather than acquire the entire company.

The investment proposal centered on connecting technology and manufacturing sites. According to a PNN press release published by Pharmabiz and Outlook Business, MedTherapy is a Boston-based cancer cell and gene therapy company offering integrated CAR-T cell contract development and manufacturing organization (CDMO) services, with technology development based in Boston and manufacturing facilities in New Delhi, India. This type of business serves therapy development and production needs, and its commercial value also depends on process capabilities and customer partnerships.

For Sudarshan Pharma, the minority investment was originally positioned as a route into the US market. The company’s stated objectives at the time included gaining access to MedTherapy’s customers, contracts and distribution network, and expanding its products and services. However, these were strategic objectives in the proposal and cannot be regarded as commercial results already achieved. The transaction value was also not clearly disclosed in the reports reviewed.

Several steps remained outstanding after the proposal was announced. In a September 15 update, the company said the investment was still undergoing due diligence, and confirmation and a resolution from MedTherapy’s board had yet to be obtained. The planned arrangement also involved legal and commercial reviews and overseas investment compliance requirements, leaving a number of steps between September’s board approval and actual closing.

What can currently be confirmed is that the investment proposal has been terminated. Publicly available information remains insufficient to determine the reason, and the termination does not provide a basis for concluding that there were problems with MedTherapy’s technology, finances or therapy efficacy. Although the S&P Capital IQ report published by MarketScreener carries an October 6 publication date, its text explicitly states that the cancellation occurred on October 7. Multiple pages reproducing the stock exchange announcement consistently list October 7. This development changes the equity investment arrangement; there is no evidence yet that it also represents any clinical or regulatory progress for any CAR-T product.

References

  1. Business Standard
  2. Pharmabiz
  3. Outlook Business / PNN syndicated release
  4. MarketScreener / S&P Capital IQ